Nine European Parkinson’s specialists issued consensus recommendations for using a newly approved dual-release levodopa formulation, IPX203, specifically for patients experiencing motor fluctuations. The guidance reflects clinician consensus rather than a new randomized efficacy trial, but it clarifies how movement-disorder teams should approach the formulation in real-world prescribing. For product strategy, the recommendations provide an evidence-backed pathway for integration into standard levodopa management schedules, which is a key step for adoption of novel levodopa-release technologies. The consensus also helps define patient selection and expected operational use cases—an important downstream factor for outcomes as clinicians attempt to reduce off-time while maintaining tolerability.